Hexartan-LNC Tablet is a combination antihypertensive medication containing Telmisartan 40 mg, Cilnidipine 10 mg, and Chlorthalidone 12.5 mg. Telmisartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, which leads to decreased blood pressure. Cilnidipine, a calcium channel blocker of the dihydropyridine class, exerts dual action by blocking L-type and N-type calcium channels, resulting in vasodilation and reduced sympathetic nerve activity. Chlorthalidone, a thiazide-like diuretic, promotes natriuresis and diuresis by inhibiting sodium reabsorption in the distal convoluted tubules, contributing to volume reduction and blood pressure lowering. The synergistic effects of these three agents provide effective management of hypertension, particularly in patients requiring multi-mechanistic intervention. Hexartan-LNC is indicated for the treatment of essential hypertension to achieve optimal blood pressure control and reduce the risk of cardiovascular events such as stroke and myocardial infarction. The combination therapy improves patient compliance by simplifying the regimen and minimizing adverse effects associated with higher doses of individual agents. Use of Hexartan-LNC should be under medical supervision, with monitoring of renal function, electrolytes, and blood pressure to ensure safety and efficacy.